Your browser doesn't support javascript.
loading
Communicating Tobacco Product Information to the Public.
Berman, Micah L; Byron, M Justin; Hemmerich, Natalie; Lindblom, Eric N; Lazard, Allison J; Peters, Ellen; Brewer, Noel T.
Afiliação
  • Berman ML; Associate professor at Ohio State University's College of Public Health and Moritz College of Law.
  • Byron MJ; Research scientist at the University of North Carolina's Lineberger Comprehensive Cancer Center.
  • Hemmerich N; Postdoctoral fellow at Ohio State University's College of Public Health.
  • Lindblom EN; Director for Tobacco Control and Food and Drug Law at Georgetown University Law Center's O'Neill Institute for National and Global Health Law.
  • Lazard AJ; Assistant professor at the University of North Carolina's School of Media and Journalism.
  • Peters E; Professor at Ohio State University's Department of Psychology.
  • Brewer NT; Professor at the University of North Carolina's Gillings School of Global Public Health.
Food Drug Law J ; 72(3): 386-405, 2017.
Article em En | MEDLINE | ID: mdl-29398886
The 2009 Family Smoking Prevention and Tobacco Control Act (TCA) requires tobacco companies to disclose information about the harmful chemicals in their products to the U.S. Food and Drug Administration (FDA). The law requires the FDA, in turn, to communicate this information to the public "in a format that is understandable and not misleading to a lay person." But how should the FDA comply with this requirement? What does it mean for information about complex chemicals to be "understandable and not misleading to a lay person"? These questions are not easy ones to answer. Disclosures about the amount of harmful chemicals (constituents) in different tobacco products may help to inform consumers, but may also conversely prompt consumers to reach incorrect or unsupported conclusions about products' relative health risks. This paper first analyzes the FDA's legal obligation to publish tobacco constituent information so that it is "understandable and not misleading to a layperson." Second, it discusses how that legal analysis has guided scientific research examining how members of the public interpret messages regarding tobacco constituents. Lastly, this paper concludes with policy recommendations for the FDA as it considers how to comply with the law's constituent disclosure requirement while still furthering its overall objective of promoting public health.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Produtos do Tabaco / Prevenção do Hábito de Fumar Tipo de estudo: Etiology_studies / Risk_factors_studies País como assunto: America do norte Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Produtos do Tabaco / Prevenção do Hábito de Fumar Tipo de estudo: Etiology_studies / Risk_factors_studies País como assunto: America do norte Idioma: En Ano de publicação: 2017 Tipo de documento: Article